GLP-1 Agonists in Type 1 Diabetes Mellitus. - Wikidata - awgldk - TriplyDB

GLP-1 Agonists in Type 1 Diabetes Mellitus.

GLP-1 Agonists in Type 1 Diabetes Mellitus.

http://www.wikidata.org/entity/Q34677451

about

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.Dapagliflozin for the treatment of type 1 diabetes mellitus.Weight Management in Patients with Type 1 Diabetes and Obesity.Orphan neuropeptides and receptors: Novel therapeutic targets.Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.β-Cell Autophagy in Diabetes Pathogenesis.Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.

P2860

Q38974881-BA291699-157D-46A2-B2F1-AB59A8B60E36 Q39354776-08EEE53B-85C0-4452-8404-4A3F8A37C927 Q41504692-2FD845F4-660E-4A6D-8346-47438391D005 Q47366066-29AC5E05-126C-4602-9F59-148CC98797D2 Q48340758-712782A3-2A07-45B8-B5AC-EEB2A45B9C17 Q52607218-4A8300B4-FA5A-40CC-A662-CB3CE716047E Q52674501-3D0A79C2-024A-4E09-B95F-774AE0A4544F

P2860

GLP-1 Agonists in Type 1 Diabetes Mellitus.

http://www.wikidata.org/entity/Q34677451

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@ast

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@en

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@nl

type

label

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@ast

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@en

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@nl

prefLabel

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@ast

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@en

GLP-1 Agonists in Type 1 Diabetes Mellitus.

@nl

P1433

Q34677451-CA882219-4A60-4168-AF83-12735BC11B75

P1476

Q34677451-BB93C195-A3C4-42EC-919E-11BEBACFE86A

P2093

Q34677451-282B6CE2-E7FA-4CAE-98AC-6D17872D4F59

Q34677451-A77D2D8A-8937-46E5-B633-9280620B0DDD

Q34677451-E9A546E3-5FE4-4866-BEF1-6AF22A71946C

P2860

Q34677451-076CB8B6-9F91-4F8E-8484-C297C5994BCF

Q34677451-2D15EE53-42A4-4F76-B259-5738F241E6C8

Q34677451-3045BD35-782D-45C5-9112-FA06CD874856

Q34677451-3BEFEC86-44CB-456D-BDE6-E4CCBDEFA707

Q34677451-3DC228D6-EDC8-4299-BC76-9D85A10BD423

Q34677451-43E1AD24-E5CA-4439-8D9D-06E4AB6F4C26

Q34677451-497327F5-FAE5-4499-8162-91C9F2CD128D

Q34677451-5206260D-69EF-4A7F-9D7C-CD4C581FAD62

Q34677451-5C5C3B9C-D515-4762-B794-B25AA20135C3

Q34677451-60425DF4-4FB2-4355-987F-E71D1A9B9062

P304

Q34677451-50DD8A84-96A0-4928-8CE9-F307C8F2FB3D

P31

Q34677451-350C7111-9450-4A66-AC30-EC1BC5247BF9

P356

Q34677451-D8950899-0139-486D-980E-1C307CFAFBCD

P407

Q34677451-764A43BA-D51D-4A5F-9113-19C0638BE34E

P433

Q34677451-97E0D4B7-20AA-49A5-88DF-9FF7CCF74B2C

P478

Q34677451-A0148156-40ED-4F54-A70B-E7A59B4EA35B

P50

Q34677451-101C141E-3314-4A13-817C-90457990A418

Q34677451-5CC6B1B4-CA9C-4F15-ABEA-C041A2183A45

Q34677451-9C62FB20-FF1B-46DB-A27D-C8095F179870

P577

Q34677451-DA7056AB-90FA-4C0D-B07A-780761B3733E

P698

Q34677451-BF7A2543-CF43-4275-8089-85CD1AF61A08

P921

Q34677451-48C035D7-239E-4F7F-A8B2-37DB2CF88C29

P356

1060028016651279

P1433

Annals of Pharmacotherapy

P1476

GLP-1 Agonists in Type 1 Diabetes Mellitus

@en

P2093

Kristin M Janzen

http://www.w3.org/2001/XMLSchema#string

Sarah A Nisly

http://www.w3.org/2001/XMLSchema#string

Taylor D Steuber

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Temporal patterns in overweight and obesity in Type 1 diabetes.

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

P304

656-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028016651279

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Taylor D Steuber

Kristin M Janzen

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27252246

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes